Oncology drug development and biotech research by Karyopharm Therapeutics

  • Oleg Tkachenko
  • 20 hours ago
Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update
Karyopharm Therapeutics' new Phase 3 results from its SENTRY trial in myelofibrosis were featured in a late-breaking oral presentation at the EHA Annual Congress on June 14. The EHA Scientific ...
  • Andrey Mastykin
  • 02.06.2026
Karyopharm Therapeutics unveils Phase 3 SENTRY trial data in myelofibrosis at ASCO26
Karyopharm Therapeutics revealed new data from its Phase 3 SENTRY trial in myelofibrosis during a late-breaking oral presentation at ASCO26. The company announced that the results are being ...
  • Ivan Andriyenko
  • 14.05.2026
Karyopharm Therapeutics sets near term milestones in cancer and myelofibrosis pipelines after Q1 update
Karyopharm Therapeutics released its first quarter financial results and outlined upcoming milestones in its endometrial cancer and myelofibrosis programs. The company stated that these ...
  • Ivan Andriyenko
  • 24.03.2026
Karyopharm Therapeutics announces topline results from Phase 3 SENTRY trial in myelofibrosis
Karyopharm Therapeutics has released topline results from its Phase 3 SENTRY clinical trial focused on treating patients with frontline myelofibrosis. The company expressed gratitude to patients, ...